These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1116 related articles for article (PubMed ID: 31922192)

  • 1. Characterization and applications of Type I CRISPR-Cas systems.
    Hidalgo-Cantabrana C; Barrangou R
    Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and Repurposing of Type I and Type II CRISPR-Cas Systems in Bacteria.
    Hidalgo-Cantabrana C; Goh YJ; Barrangou R
    J Mol Biol; 2019 Jan; 431(1):21-33. PubMed ID: 30261168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
    Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
    J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR technologies for bacterial systems: Current achievements and future directions.
    Choi KR; Lee SY
    Biotechnol Adv; 2016 Nov; 34(7):1180-1209. PubMed ID: 27566508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology.
    Ishino Y; Krupovic M; Forterre P
    J Bacteriol; 2018 Apr; 200(7):. PubMed ID: 29358495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems.
    O'Connell MR
    J Mol Biol; 2019 Jan; 431(1):66-87. PubMed ID: 29940185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing type I-F CRISPR-Cas system as a transcriptional activation tool in human cells.
    Chen Y; Liu J; Zhi S; Zheng Q; Ma W; Huang J; Liu Y; Liu D; Liang P; Songyang Z
    Nat Commun; 2020 Jun; 11(1):3136. PubMed ID: 32561716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
    Xu R; Wei P; Yang J
    Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cas9, Cpf1 and C2c1/2/3-What's next?
    Nakade S; Yamamoto T; Sakuma T
    Bioengineered; 2017 May; 8(3):265-273. PubMed ID: 28140746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a.
    Swartjes T; Staals RHJ; van der Oost J
    Biochem Soc Trans; 2020 Feb; 48(1):207-219. PubMed ID: 31872209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rapidly advancing Class 2 CRISPR-Cas technologies: A customizable toolbox for molecular manipulations.
    Wang J; Zhang C; Feng B
    J Cell Mol Med; 2020 Mar; 24(6):3256-3270. PubMed ID: 32037739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas System: History and Prospects as a Genome Editing Tool in Microorganisms.
    Javed MR; Sadaf M; Ahmed T; Jamil A; Nawaz M; Abbas H; Ijaz A
    Curr Microbiol; 2018 Dec; 75(12):1675-1683. PubMed ID: 30078067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CRISPR Growth Spurt: from Bench to Clinic on Versatile Small RNAs.
    Bayat H; Omidi M; Rajabibazl M; Sabri S; Rahimpour A
    J Microbiol Biotechnol; 2017 Feb; 27(2):207-218. PubMed ID: 27840399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing CRISPR-Cas systems for bacterial genome editing.
    Selle K; Barrangou R
    Trends Microbiol; 2015 Apr; 23(4):225-32. PubMed ID: 25698413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diversity and evolution of class 2 CRISPR-Cas systems.
    Shmakov S; Smargon A; Scott D; Cox D; Pyzocha N; Yan W; Abudayyeh OO; Gootenberg JS; Makarova KS; Wolf YI; Severinov K; Zhang F; Koonin EV
    Nat Rev Microbiol; 2017 Mar; 15(3):169-182. PubMed ID: 28111461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Control of Genome Editing in Human Cells by Chemical-Inducible CRISPR-Cas Systems.
    Liu KI; Ramli MNB; Sutrisnoh NB; Tan MH
    Methods Mol Biol; 2018; 1772():267-288. PubMed ID: 29754234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The new generation tool for CRISPR genome editing: CRISPR/Cpf1].
    Yang F; Li Y
    Sheng Wu Gong Cheng Xue Bao; 2017 Mar; 33(3):361-371. PubMed ID: 28941336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas systems in oral microbiome: From immune defense to physiological regulation.
    Gong T; Zeng J; Tang B; Zhou X; Li Y
    Mol Oral Microbiol; 2020 Apr; 35(2):41-48. PubMed ID: 31995666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting CRISPR/Cas: interference mechanisms and applications.
    Richter H; Randau L; Plagens A
    Int J Mol Sci; 2013 Jul; 14(7):14518-31. PubMed ID: 23857052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptation in CRISPR-Cas Systems.
    Sternberg SH; Richter H; Charpentier E; Qimron U
    Mol Cell; 2016 Mar; 61(6):797-808. PubMed ID: 26949040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.